Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience
ConclusionOur study describes both the spectrum of cutaneous AE of palbociclib and endocrine therapy, and approaches to management. Prompt management may limit the negative impact on patients, facilitating beneficial continuation of palbociclib and endocrine therapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Corticosteroid Therapy | Dermatitis | Dermatology | Endocrine Therapy | HER2 | Hives | Hormones | Hydroxychloroquine | Lupus | Oral Cancer | Pemphigoid | Study | Toxicology